Eli Lilly and Company
A corporate partner since 2022
Lilly and UNICEF are collaborating to strengthen health care for 10 million children and adolescents living with non-communicable diseases
Every year, nearly 1 million people under the age of 20 die from often treatable non-communicable diseases (NCD), including type 1 diabetes, cancer, congenital and rheumatic heart disease, sickle cell disease and asthma, based on data from the Global Burden of Disease Study.
In February 2022, Eli Lilly and Company and UNICEF launched a new collaboration to change the global landscape of childhood and adolescent non-communicable diseases, focusing on prevention, detection, treatment and support.
The initial four-year commitment supports UNICEF’s efforts to address NCD risk factors and strengthen health systems to provide care for child and adolescent patients in Bangladesh, Malawi, Nepal, the Philippines and Zimbabwe.
The collaboration aims to accelerate progress toward achieving Sustainable Development Goal 3 to ensure healthy lives and promote well-being for all by addressing and treating non-communicable diseases in low- and middle-income countries, ensuring fewer preventable deaths for children and young people.
UNICEF does not endorse any brand, company, product or service.
Last updated 20 March 2023
